5-溴尿苷单磷酸二钠盐 | 2149-79-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 中文名称: 5-溴尿苷单磷酸二钠盐
• 中文别名: 5-溴-尿苷-5'-单磷酸二钠；5-溴尿苷单磷酸
• 英文名称: 5-Brom-uridin-5'-phosphat
• 英文别名: 5-Bromouridine 5'-monophosphate；[(2R,3S,4R,5R)-5-(5-bromo-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 2149-79-3
• 化学式: C₉H₁₂BrN₂O₉P
• 分子量: 403.08
• InChiKey: IDPVUMJNEZFMNU-UAKXSSHOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  166
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5-溴尿苷单磷酸二钠盐 在 Meiothermus ruber polyphosphate kinase D₁₂₇S 、 magnesium chloride 作用下， 以 aq. buffer 为溶剂， 生成 5-Bromo-UDP
  参考文献：
  名称：

  10.1002/cctc.202400181

  摘要：

  AbstractPolyphosphate kinases (PPKs) are valuable biocatalysts for ATP cofactor regeneration as well as for the phosphorylation of non‐canonical nucleotides. The versatility of PPKs in the latter application is defined by their substrate scope. In this study, we investigate the substrate spectrum of the PPK2‐III enzyme from Meiothermus ruber (MrPPK) for the conversion of canonical and non‐canonical (deoxy)‐ribonucleotides. The enzyme shows high substrate promiscuity for purine and to minor degree pyrimidine substrates, with an overall preference for the native substrate AMP. With structure guided rational amino acid exchanges in the active site, we produced an MrPPK variant with improved activity for a broad variety of purine nucleotides. While the preference for AMP is lost, conversion of nucleotides without a 6‐amino function at the purine moiety is increased. This MrPPK variant is a versatile biocatalyst for the synthesis of non‐canonical nucleotides and could also be useful as a GTP cofactor regeneration system.

  DOI：

  10.1002/cctc.202400181
• 作为产物：
  描述：

  尿苷5-单磷酸 在 溴 作用下， 生成 5-溴尿苷单磷酸二钠盐
  参考文献：
  名称：

  OMP脱羧酶反应中O2处的大量氧同位素效应：机理上的意义。

  摘要：

  Orotidine-5'-单磷酸脱羧酶（OMP脱羧酶，ODCase）催化orotidine-5'-单磷酸（OMP）脱羧为尿苷5'-单磷酸（UMP）。尽管进行了广泛的酶学，结构和计算研究，但ODCase的机制仍未完全表征。在此，对于自然丰度底物和为了进行远程双标记同位素效应程序而合成的底物混合物，均以底物的O 2为远程位置，测量了碳动力学同位素效应。测得该底物混合物对酶促脱羧的碳动力学同位素效应为1.0199 +/- 0.0007，而自然丰度OMP的值为1.0289 +/- 0.0009，表明（18）O2同位素效应为0.991 +/- 0.001。使用从先前同位素效应数据得出的计算承诺因子，该值等于约0.983的固有同位素效应。测得的（18）O2同位素效应需要一种或多种酶促过程的机制，包括结合和/或化学作用，从而促成这种实质性的反同位素效应。（18）针对两种拟议的机理计算了O2的动力学同位素

  DOI：

  10.1039/b812979g

文献信息

• ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID
  申请人：Hoerr Ingmar

  公开号：US20070280929A1

  公开（公告）日：2007-12-06

  The present invention relates to an immune-stimulating adjuvant in the form of a lipid-modified nucleic acid, optionally in combination with further adjuvants. The invention relates further to a pharmaceutical composition and to a vaccine, each containing an immune-stimulating adjuvant according to the invention, at least one active ingredient and optionally a pharmaceutically acceptable carrier and/or further auxiliary substances and additives and/or further adjuvants. The present invention relates likewise to the use of the pharmaceutical composition according to the invention and of the vaccine according to the invention for the treatment of infectious diseases or cancer diseases. Likewise, the present invention includes the use of the immune-stimulating adjuvant according to the invention in the preparation of a pharmaceutical composition for the treatment of cancer diseases or infectious diseases.

  本发明涉及一种免疫刺激佐剂，其形式为脂质修饰的核酸，可选地与其他佐剂结合。该发明还涉及一种含有根据本发明的免疫刺激佐剂、至少一种活性成分以及可选的药用载体和/或其他辅助物质和添加剂和/或其他佐剂的药物组合物和疫苗。本发明还涉及根据本发明的药物组合物和疫苗用于治疗传染病或癌症的用途。同样，本发明包括根据本发明的免疫刺激佐剂用于制备用于治疗癌症或传染病的药物组合物的用途。
• Enzymatic Production of Non-Natural Nucleoside-5′-Monophosphates by a Thermostable Uracil Phosphoribosyltransferase
  作者：Jon del Arco、Javier Acosta、Humberto M. Pereira、Almudena Perona、Neratur K. Lokanath、Naoki Kunishima、Jesús Fernández-Lucas

  DOI：10.1002/cctc.201701223

  日期：2018.1.23

  TtUPRT has been determined by protein crystallography, and its substrate specificity and biochemical characteristics have been analyzed, providing new structural insights into the substrate‐binding mode. Biochemical characterization of the recombinant protein indicates that the enzyme is a homotetramer, with activity and stability across a broad range of temperatures (50–80 °C), pH (5.5–9) and ionic strength

  使用酶作为生物催化剂来合成修饰的5'-单磷酸核苷（NMP）是传统的多步化学方法的有趣替代方法，该方法具有多种优势，例如立体，区域和对映选择性，简单的下游加工以及反应条件温和。在本文中，我们报道了嗜热栖热菌HB8（Tt UPRT）的尿嘧啶磷酸核糖基转移酶的重组表达，生产和纯化。Tt的结构UPRT已通过蛋白质晶体学确定，并对其底物特异性和生化特性进行了分析，从而为底物结合模式提供了新的结构见解。重组蛋白的生化特性表明该酶是同四聚体，在很宽的温度范围（50–80°C），pH（5.5–9）和离子强度（0–500 m m NaCl）中均具有活性和稳定性。令人惊讶的是，Tt UPRT能够识别几种5和6-取代的嘧啶作为底物。这些实验结果表明，Tt UPRT可能是合成修饰NMP的有价值的生物催化剂。
• Alpha-tocopherol (halo) uridine phosphoric acid diester, salts thereof, and methods for producing the same
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP0226753A2

  公开（公告）日：1987-07-01

  A compound represented by the formula (wherein X represents a hydrogen atom or a halogen atom) provided in accordance with the invention are novel compound of value as nonsteroidal antiinflamatory agents. Alpha-tocopherol 5-halouridine phosphoric acid diesters, in particular, are expected to be employable for antitumor agents as well.

  由式 (其中 X 代表氢原子或卤原子）的新型化合物具有非甾体抗炎剂的价值。特别是α-生育酚-5-胡萝卜苷磷酸二酯，预计也可用作抗肿瘤剂。
• Complexes of RNA and cationic peptides for transfection and for immunostimulation
  申请人：CureVac GmbH

  公开号：EP2484770A1

  公开（公告）日：2012-08-08

  The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide has a length of 8 to 15 amino acids and has the empirical formula (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x with the majority of the residues being selected from Arg, Lys, His, Orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.

  本发明涉及一种复合 RNA，包括至少一种与一种或多种寡肽复合的 RNA，其中寡肽的长度为 8 至 15 个氨基酸，具有经验式 (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x，大部分残基选自 Arg、Lys、His、Orn。本发明进一步涉及一种转染细胞或生物体的方法，从而应用本发明的复合 RNA。此外，本文还公开了包含本发明络合 RNA 的药物组合物和试剂盒，以及本发明络合 RNA 用于转染细胞、组织或生物体和/或调节、优选诱导或增强免疫反应的用途。
• Pooled adapter strategy for reducing bias in small RNA characterization
  申请人：Mount Sinai School of Medicine

  公开号：US10557169B2

  公开（公告）日：2020-02-11

  Modified nucleic acid adapters are provided that collectively provide a mixture of nucleotides at the 3′ end of 5′ adapters and at the 5′ end of 3′ adapters such that at least one adapter in each set has any given nucleotide at position 1, i.e., the nucleotide position available for ligation to a small RNA, and has any given nucleotide at position 2 adjacent to position 1 for use in overcoming bias during nucleic acid manipulation, such as small RNA characterization and/or profiling by, e.g., deep sequencing, along with methods for use of the modified adapters in small RNA characterization. The modified adapters have at least two mixed nucleotides at the adapter terminus to be ligated to a nucleic acid such as a small RNA.

  提供了经过修饰的核酸适配体，这些适配体在5′适配体的3′端和3′适配体的5′端共同提供了核苷酸的混合物，使得每组适配体中至少有一个适配体在位置1上具有任何给定的核苷酸，即、的核苷酸位置，并在与位置 1 相邻的位置 2 上具有任意给定的核苷酸，以用于克服核酸操作过程中的偏差，例如通过深度测序等方法进行小 RNA 表征和/或剖析，以及在小 RNA 表征中使用修饰适配体的方法。经修饰的适配体在适配体末端至少有两个混合核苷酸，可与核酸如小 RNA 连接。